Breaking Finance News

Morgan Stanley upgraded Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to Overweight in a report released today.

Morgan Stanley has upgraded Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to Overweight in a report released on 05/25/2017.

Yesterday Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) traded -2.26% lower at $101.02. The company’s 50-day moving average is $142.33 and its 200-day moving average is $127.81. The last stock close price is down 6.31% from the 200-day moving average, compared to the S&P 500 which has increased 0.02% over the same time. 1,917,547 shares of the stock traded hands, up from an avg. volume of 1,552,850

Recent Performance Chart

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Alexion Pharmaceuticals, Inc. has PE ratio of 58.92 with a one year low of $96.18 and a one year high of $149.34 and has a market capitalization of $0.

In addition to Morgan Stanley reporting its target price, a total of 18 firms have issued a report on the stock. The consensus target price is $187.61 with 7 firms rating the stock a strong buy, 6 brokers rating the stock a buy, seven analysts rating the company a hold, zero analysts rating the company a underperform, and lastly zero brokerages rating the company a sell.

General Company Details For Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous). Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP). Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). It is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *